Takeda recently announced positive results from a phase 2 clinical trial of their investigational therapy (Mezagitamab), to treat patients with persistent or chronic primary immune thrombocytopenia (ITP). The therapy is developed with laboratory…
NBDF is pleased to announce HANDI Highlights, which is designed to connect the bleeding disorders community with timely, practical, and readily-accessible resources.This March 2024 edition includes several introductory resources to…
#block-recentonlineeducation {
display:none;
}
Aprende sobre de la cascada de coagulación Acompáñenos a una aventura en 3D en este vídeo sobre cómo se coagula la sangre cuando hay una hemorragia o una herida. La animación 3D de este vídeo…
For Immediate Release CONTACT: Carrie Strehlau and Kyla Clark National Bleeding Disorders Foundation 212-382-3773 kclark@bleeding.org National Bleeding Disorders Foundation Celebrates Five…
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for IXINITY® (Medexus), a recombinant factor replacement therapy to treat patients with hemophilia B. The new approval expands the product…
#block-recentonlineeducation {
display:none;
}
Aprende sobre la terapia de reemplazo de factoresUno de los tratamientos utilizados para algunos trastornos hemorrágicos es la terapia de reemplazo de factores. El siguiente vídeo en 3D muestra…
NBDF recently learned that Novo Nordisk now has 3,000 IU vial size of Rebinyn® back in stock. Rebinyn is the company's recombinant factor IX extended half-life therapy for the treatment of hemophilia B. It is indicated for the on-demand treatment…
The Pittsburgh Pirates are teaming up with Western PA Bleeding Disorders Foundation to help enrich the lives of those with bleeding disorders in Western Pennsylvania. $10 of each ticket sold will benefit the Western PA Bleeding Disorders Foundation…
.stack {
float: left;
margin: 0px 20px 0px 20px;
}
@media only screen and (max-width: 600px){
.stack {
float: none;
}
}
Speaker: Guy Young, MDRegister to join us and learn about treatment options for hemophilia A…
Government Relations Update – March 2024Federal: NBDF’s 2024 Washington Days was held March 6-8. NBDF is grateful to the more than 400 volunteer advocates from forty-four states who participated in the 231…